SARS in China and Hong KongNova Publishers, 2006 - 94 ˹éÒ This book undertakes a general review on the major infectious diseases in Hong Kong and Mainland China. Secondly, it will set out the future directions for better preparedness in the fight against infectious diseases particularly the emerging new infections in the 21st Century. It also discusses the severe acute respiratory syndrome (SARS), also called infectious atypical pneumonia in China, is an emerging infectious disease caused by a novel variant of coronavirus (SARS-associated coronavirus, SARS-CoV). It is mainly characterised by pulmonary infection with high infectivity and fatality. SARS swept across almost every continent of the globe, and has currently involved 32 countries and regions, including the mainland of China, Hong Kong, Taiwan, North America and Europe. The condition is hard especially in China. Chinese scientists and healthcare workers co-operated closely with scientists around the world to fight with the disease. On April 16, 2003, World Health Organization (WHO) formally declared that SARS-CoV was an etiological agent of SARS. Currently, there is no specific and effective therapy and prevention method for SARS. However, this disease can be prevented, and it is also curable and controllable. The main treatments include corticosteroid therapy, anti-viral agents, anti-infection, mechanical ventilation and medical isolation. With the endeavour of the Chinese Government, medical staffs and other related professionals, SARS has been controlled in China. Scientists around the world, including Chinese scientists have made a great progress in SARS research from that time on. A review is presented of the history of SARS and the progress in SARS research, especially in China. |
¤ÓáÅÐÇÅÕ·Õ辺ºèÍÂ
acute respiratory syndrome AIDS alveolar epithelial cells Amoy Gardens antibody antiviral areas atypical pneumonia avascular necrosis avian influenza Beijing blood chest chickens Chinese civet cat clinical manifestations collaboration communicable diseases confirmed Control and Prevention control of infectious countries damp-heat Department of Health detection diseases in Hong drug early epidemiological global Government Guangdong Province Guangzhou H5N1 avian influenza health authorities health care workers healthcare high infectivity HIV/AIDS Hong Kong Hospital Authority human Infectious Atypical Pneumonia infectious diseases infectious diseases control investigation isolation Kong and Mainland laboratory lung lymphocytes Mainland China March nasopharyngeal aspirate Notification pathogenic population prevention and control programme public health pulmonary region reported respiratory syndrome SARS Ribavirin RT-PCR samples SARS patients SARS research SARS virus SARS-CoV sector serum severe acute respiratory Shanxi Source spread surveillance symptoms TB control tested therapy tissue treatment Tuberculosis vaccine ventilation viral viruses World Health Organization
º·¤ÇÒÁ·Õèà»ç¹·Õè¹ÔÂÁ
˹éÒ 87 - The Acute Respiratory Distress Syndrome Network. Ventilation with lower tidal volumes as compared with traditional tidal volumes for acute lung injury and the acute respiratory distress syndrome.
˹éÒ 87 - Science, 2003;300: 1763- 1767 [53] Moller JC, Schaible T. Roll C, et al. Treatment with bovine surfactant in severe acute respiratory distress syndrome in children: a randomized multicenter study. Intensive Care Med, 2003:29:437-46 [54] Cao YZ, Nie QH. Current status of SARS on diagnosis and treatment. Chinese Critical Care Medicine ,2003 ; 1 5 :44 1 -444 [55] Xiao X.